Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis

Gene Therapy

Volumn 7, Issue 22, 2000, Pages 1930-1939

  Cottard, V ^a,b   Mulleman, D ^a,b   Bouille, P ^c   Mezzina, M ^c   Boissier, M C ^a,b,d,e   Bessis, N ^a,b,e  

^a UNIVERSITÉ PARIS 13   (France)

^b Groupe de Recherche en Immunopathologie   (France)

^c GÉNÉTHON   (France)

^d AVICENNE HOSPITAL   (France)

^e INSERM   (France)

Author keywords

Adeno associated virus; Animal models; Cytokines; Inflammation; Rheumatoid arthritis

Indexed keywords

BETA GALACTOSIDASE; COLLAGEN TYPE 2; COMPLEMENTARY DNA; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCATION; GENE TARGETING; GENE THERAPY; HEART; HEEL; LIVER; LUNG; MALE; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVITIS; TRANSGENE; TREATMENT OUTCOME; VIRUS RECOMBINANT;

ADENO-ASSOCIATED VIRUS; ANIMALIA; DNA VIRUSES;

EID: 0033676265     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301324     Document Type: Article

References (66)

1. Rheumatoid arthritis. Pathophysiology and implications for therapy
2. Future trends in the treatment of rheumatoid arthritis: Cytokine targets
3. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis
4. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
5. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
6. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra
7. Direct adenovirus-mediated gene transfer of interleukin-1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects
8. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee
9. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy
10. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist
11. The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis
12. Autoimmunity to type II collagen an experimental model of arthritis
13. Immunisation against heterologous type II collagen induces arthritis in mice
14. A proinflammatory role for IL-18 in rheumatoid arthritis
15. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium
16. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13
17. Modulation of proinflammatory cytokine production in tumour necrosis factor-alpha (TNF-alpha)-transgenic mice by treatment with cells engineered to secrete IL-4, IL-10 or IL-13
18. Differential effects of interleukins 10 and 4 on the production of interleukin-6 by blood and synovium monocytes in rheumatoid arthritis
19. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis
20. Conversion in vivo from an early dominant Th0/Th1 response to a Th2 phenotype during the development of collagen-induced arthritis
21. Encapsulation in hollow fibres of xenogeneic cells engineered to secrete IL-4 or IL-13 ameliorates murine collagen-induced arthritis (CIA)
22. Suppression of collagen-induced arthritis by continuous administration of IL-4
23. Interleukin-10 inhibition of the progression of established collagen-induced arthritis
24. Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis
25. Gene therapy for rheumatic diseases
26. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA
27. Adenovirus mediated transfer of viral IL-10 gene inhibits collagen-induced arthritis
28. Adeno-associated viral vectors for gene transfer and gene therapy
29. Immune responses to adenovirus and adeno-associated virus in humans
30. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction
31. Intra-articular IL-4 gene therapy in arthritis: Anti-inflammatory effect and enhanced th2 activity
32. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws
33. Viral IL-10 and soluble TNF receptor act synergistically to inhibit collagen-induced arthritis following adenovirus-mediated gene transfer
34. Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees
35. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10
36. Interleukin 4, but not interleukin 10, regulates the production of inflammation mediators by rheumatoid synoviocytes
37. Interleukin-4 suppression of interleukin-1-induced transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human synovial fibroblasts
38. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4
39. Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells
40. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice
41. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis
42. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice
43. Recombinant adeno-associated virus for muscle directed gene therapy
44. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector
45. Inducible long-term gene expression in brain with adeno-associated virus gene transfer
46. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats
47. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
48. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates
49. Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis
50. Feasibility of adenovirus-mediated nonsurgical synovectomy in collagen-induced arthritis-affected rhesus monkeys
51. Gene transfer to human rheumatoid synovial tissue engrafted in SCID mice
52. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer
53. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers
54. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector
55. Transduction by adeno-associated virus vectors in the rabbit airway: Efficiency, persistence, and readministration
56. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration
57. Empirical advantages of adeno-associated viral vectors for in vivo gene therapy for arthritis
58. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer
59. Current protocols in human genetics
60. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus
61. Strategies for the isolation and purification of retroviral vectors for gene therapy
62. Biochemical recovery and purification of gene therapy vectors
63. Factors influencing recombinant adeno-associated virus production
64. Arthritogenicity of minor cartilage collagens (type IX and XI) in mice
65. Experimental autoimmune arthritis in mice. I. Homologous type II collagen is responsible for self-perpetuating chronic polyarthritis
66. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors